COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #81 of 237
7/9 Late treatment study
Rivera-Izquierdo et al., Medicina Clínica, doi:10.1016/j.medcli.2020.06.025 (Peer Reviewed)
Agentes terapéuticos utilizados en 238 pacientes hospitalizados por COVID-19 y su relación con la mortalidad
Source   PDF   Share   Tweet
Retrospective 238 hospitalized patients in Spain showing lower mortality with HCQ, adjusted hazard ratio aHR 0.81 [0.24-2.76].

Rivera et al., 7/9/2020, retrospective, Spain, Europe, peer-reviewed, 21 authors.
risk of death, 19.0% lower, RR 0.81, p = 0.75, treatment 215, control 23.
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit